Peter Alping

1.3k total citations · 1 hit paper
13 papers, 950 citations indexed

About

Peter Alping is a scholar working on Pathology and Forensic Medicine, Oncology and Neurology. According to data from OpenAlex, Peter Alping has authored 13 papers receiving a total of 950 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pathology and Forensic Medicine, 8 papers in Oncology and 4 papers in Neurology. Recurrent topics in Peter Alping's work include Multiple Sclerosis Research Studies (10 papers), Polyomavirus and related diseases (7 papers) and Peripheral Neuropathies and Disorders (4 papers). Peter Alping is often cited by papers focused on Multiple Sclerosis Research Studies (10 papers), Polyomavirus and related diseases (7 papers) and Peripheral Neuropathies and Disorders (4 papers). Peter Alping collaborates with scholars based in Sweden, United States and United Kingdom. Peter Alping's co-authors include Fredrik Piehl, Jan Lycke, Katharina Fink, Jonatan Salzer, Anders Svenningsson, Thomas Frisell, Annette Langer‐Gould, Clas Malmeström, Markus Axelsson and Lenka Novakova and has published in prestigious journals such as Neurology, Annals of Neurology and Epidemiology.

In The Last Decade

Peter Alping

13 papers receiving 932 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

2019 346 citations Gustavo Luna, Peter Alping et al. JAMA Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Alping Sweden	7	780	348	320	246	132	13	950
Neil Minton United States	11	462 0.6×	146 0.4×	133 0.4×	155 0.6×	61 0.5×	24	818
Lana Zhovtis Ryerson United States	12	374 0.5×	188 0.5×	181 0.6×	86 0.3×	121 0.9×	36	509
Victoria Fernández Spain	13	302 0.4×	82 0.2×	118 0.4×	93 0.4×	18 0.1×	40	483
Martin Diebold Germany	16	200 0.3×	86 0.2×	119 0.4×	242 1.0×	31 0.2×	39	708
Salvatore Buffardi Italy	12	176 0.2×	86 0.2×	164 0.5×	44 0.2×	97 0.7×	43	487
Marco Rabusin Italy	15	168 0.2×	45 0.1×	125 0.4×	195 0.8×	60 0.5×	43	818
Rong‐Long Chen Taiwan	16	152 0.2×	61 0.2×	348 1.1×	289 1.2×	214 1.6×	56	920
Deborah S. Goddard United States	13	163 0.2×	154 0.4×	170 0.5×	71 0.3×	35 0.3×	14	706
Hanna Kuusisto Finland	13	249 0.3×	81 0.2×	126 0.4×	102 0.4×	7 0.1×	42	429
Jutta K. Neuenburg United States	10	216 0.3×	31 0.1×	163 0.5×	71 0.3×	106 0.8×	27	649

Countries citing papers authored by Peter Alping

Since Specialization

Citations

This map shows the geographic impact of Peter Alping's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Alping with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Alping more than expected).

Fields of papers citing papers by Peter Alping

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Alping. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Alping. The network helps show where Peter Alping may publish in the future.

Co-authorship network of co-authors of Peter Alping

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Alping. A scholar is included among the top collaborators of Peter Alping based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Alping. Peter Alping is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Alping, Peter, Thomas Frisell, Anna He, et al.. (2025). Completeness and generalizability of the Swedish MS register. European Journal of Epidemiology. 40(8). 905–913. 1 indexed citations

Piehl, Fredrik, Peter Alping, Simon Englund, et al.. (2024). COMBAT‐MS: A Population‐Based Observational Cohort Study Addressing the Benefit–Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab. Annals of Neurology. 96(4). 678–693. 3 indexed citations

Alping, Peter, Martin Neovius, Fredrik Piehl, & Thomas Frisell. (2024). Real‐World Healthcare Cost Savings and Reduced Relapse Rate with Off‐Label Rituximab versus Disease‐Modifying Treatments Approved for Relapsing–Remitting Multiple Sclerosis: A Nationwide Cost‐Effectiveness Study. Annals of Neurology. 95(6). 1099–1111. 1 indexed citations

Frisell, Thomas, et al.. (2024). Hospital‐Treated Infections and Risk of Disability Worsening in Multiple Sclerosis. Annals of Neurology. 96(4). 694–703. 2 indexed citations

Alping, Peter. (2023). Disease‐modifying therapies in multiple sclerosis: A focused review of rituximab. Basic & Clinical Pharmacology & Toxicology. 133(5). 550–564. 2 indexed citations

Fink, Katharina, Peter Alping, Simon Englund, et al.. (2023). Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study. Multiple Sclerosis Journal. 29(6). 731–740. 8 indexed citations

Alping, Peter, Joachim Burman, Jan Lycke, Thomas Frisell, & Fredrik Piehl. (2021). Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis. Neurology. 96(11). e1574–e1584. 13 indexed citations

Alping, Peter, Johan Askling, Joachim Burman, et al.. (2020). Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Annals of Neurology. 87(5). 688–699. 97 indexed citations

Luna, Gustavo, Peter Alping, Joachim Burman, et al.. (2019). Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurology. 77(2). 184–184. 346 indexed citations breakdown →

10.

Alping, Peter, Fredrik Piehl, Annette Langer‐Gould, & Thomas Frisell. (2018). Validation of the Swedish Multiple Sclerosis Register. Epidemiology. 30(2). 230–233. 46 indexed citations

11.

Alping, Peter, Thomas Frisell, Lenka Novakova, et al.. (2016). Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology. 79(6). 950–958. 168 indexed citations

12.

Salzer, Jonatan, Peter Alping, Lenka Novakova, et al.. (2016). Rituximab in multiple sclerosis. Neurology. 87(20). 2074–2081. 261 indexed citations

13.

Alping, Peter, Lenka Novakova, Jonatan Salzer, et al.. (2015). Superior efficacy and tolerability of rituximab as compared to fingolimod for MS patients switching from natalizumab due to positive JC virus serology. Multiple Sclerosis Journal. 21(11). 555–555. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact